belean_coronavirus_guide_startup

COVID-19: Guide de survie des start-ups

Cliquez ici pour télécharger gratuitement notre guide de survie des start-ups face à la crise du COVID-19. Les nouvelles et le stress associés au COVID-19 dans le monde entier créent le doute, l’incertitude et l’anxiété parmi les dirigeants, les employés et les clients. Au-delà des mesures de bon sens prises par le gouvernement, nous voulons, chez beLean.net,[…]

savics_coronavirus_datatocare

Savics’ DataToCare software will be used to collect, gather and analyze COVID-19 test results

Savics is collaborating since more than 2 weeks with KU Leuven and DNAlytics to collect, gather and analyze COVID-19 test results. DataToCare COVID-19 is/will be used by all 7 University Laboratories across Belgium that support and unload the Belgian COVID-19 Reference Laboratory from UZ Leuven. DataToCare COVID-19 is a software installed in laboratories that capture COVID-19 test results and[…]

univercells_coronavirus_bultot

Univercells in the race for the coronavirus vaccine

With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot. Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 15,000-square-meter[…]

pdcLine-Pharma-dendritic-cell-cancer-vaccine

PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate targeting non-small cell lung cancer

Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]